By Y. Peter Kang ( October 20, 2015, 9:38 PM EDT) -- A California federal judge on Tuesday refused to toss a surgical center's proposed class action accusing Allergan of licensing a Korean-made drug arguably superior to its Botox treatment in order to unlawfully keep Botox prices high, saying the center adequately alleged the deal resulted in direct buyers paying higher prices....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.